HTG Named as FiReStarter
HTG Selected as a FiReStarter Company at Future in Review 2008 Conference
FiReStarter Program Recognizes Businesses with Startup Technology
Poised to Effect Positive Change
Tucson, Ariz.—June 6, 2008—HTG, Inc., the provider of the qNPA™ system, a novel array-based gene expression technology and service partner for researchers in academia and the drug discovery industry, today announced that the company was selected as one of the ten FiReStarter companies recognized at the sixth annual Future in Review (FiRe) conference held May 20-23rd in San Diego, California. The ten businesses were selected by the editorial staff at the Strategic News Service (SNS) from the hundreds of sponsor recommended companies.
“HTG was nominated by our members and selected by SNS as a FiReStarter because the company’s gene expression technology has the potential to profoundly impact healthcare, along the research-to-application continuum,” commented Mark Anderson, producer of the Future in Review conference and editor of Strategic News Service. “HTG represents the type of company we are interested in highlighting – companies with innovative technologies we believe will change our world in a positive way.”
At the conference HTG CEO T.J. Johnson presented his views on the impact that providing researchers with better discovery tools will have on healthcare. “The American healthcare system is facing a triple threat: rising healthcare costs, quality and outcomes below our aspirations, and the “Silver Tsunami” of aging “baby boomers” entering the prime healthcare consuming years,” Johnson said. “HTG is making it easier for researchers in academia and industry to quickly, accurately and cost-effectively analyze gene expression by eliminating entire steps in the drug-discovery workflow and providing a new level of precision. We believe our Multiplexed Mini-Microarrays (m3) provide a new level of capability for researchers today and clinicians in the near future as we enter into diagnostics.”
HTG’s qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development. HTG’s platform allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification. The platform provides high-quality quantitative test results, enabling clients to compress drug discovery and development program timelines, increase program successes and reduce costs.
About FiRE
Hosted by Mark Anderson, founder and publisher of the Strategic News Service, the FiRe conference exposes world experts and participants to new ideas in a manner that produces an accurate portrait of the future in technology, including nanotechnology, space travel, biology and medical diagnostics, policy, and other fields that contribute to technology outcomes.
About HTG
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital.
